CDEK
← All drugs Report issue

foralumab

mAbexperimental

Foralumab (TZLS-401), being researched by Tiziana Life Sciences) is a fully human monoclonal antibody that binds to CD3 epsilon of the T cell receptor-CD3 complex. It is currently being studied in a randomized, double-blind placebo-controlled, multicenter dose-ranging study in a nasal formulation in patients with non-active secondary progressive multiple sclerosis (SPMS). — Wikipedia

Clinical trial activity

10 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2017 (NCT03291249)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06868628Phase 2May 19, 2025Tiziana Life Sciences, PLC
NCT06890923Phase 2Mar 4, 2025Tiziana Life Sciences, PLC
NCT06489548Phase 2Sep 30, 2024Harvard University, Tiziana Life Sciences, PLC
NCT06292923Phase 2Nov 15, 2023Tiziana Life Sciences, PLC
NCT05029609Phase 1Oct 31, 2021Tiziana Life Sciences, PLC
NCT05028946Phase 1Oct 28, 2021Tiziana Life Sciences, PLC
NCT04983446Phase 2Oct 25, 2021Tiziana Life Sciences, PLC
NCT06879067Phase 1Nov 12, 2018Tiziana Life Sciences, PLC
NCT03291249Phase 2Dec 1, 2017Tiziana Life Sciences, PLC
NCT06802328N/A—Tiziana Life Sciences, PLC
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tiziana Life Sciences, PLCFor profit10932017
Harvard UniversityAcademic/Hospital1112024
2 organizations
Page 1 / 1